ILD/DPLD of known origin最新文献_第6页

Impact of BAL lymphocytosis and honeycombing presence on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis BAL淋巴细胞增多和蜂窝状存在对皮质类固醇治疗纤维化超敏性肺炎效果的影响

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa3601

L. D. Sadeleer, F. Hermans, E. D. Dycker, J. Yserbyt, J. Verschakelen, E. Verbeken, G. Verleden, S. Verleden, W. Wuyts

引用次数: 3

Factors associated with increased arterial stiffness in patients with chronic hypersensitivity pneumonitis 慢性过敏性肺炎患者动脉僵硬度增高的相关因素

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa5187

E. Leonova, E. Shmelev

{"title":"Factors associated with increased arterial stiffness in patients with chronic hypersensitivity pneumonitis","authors":"E. Leonova, E. Shmelev","doi":"10.1183/13993003.congress-2019.pa5187","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa5187","url":null,"abstract":"Background: Cardiovascular diseases are the most common comorbidities among patients with chronic lung diseases. Arterial stiffness (AS) is one of the most potent prognostic factors of cardiovascular morbidity and mortality. However, there is very little literature describing the factors associated with the increase of AS among patients with chronic hypersensitivity pneumonitis (HP). Aims and Objectives: were to investigate arterial stiffness and determine factors associated with its increase among patients with HP. Methods: We identified 106 patients with chronic HP, who underwent spirometry, plethysmography, diffusing capacity of carbon monoxide (DLCO), pulmonary high resolution computed tomography (HRCT), bronchoscopy and lung biopsy. AS was measured by pulse wave velocity (PWV). BMI, the duration of HP and the exacerbations frequency were evaluated. Results: The increase of arterial stiffness was found in 71 (67%) of patients. Correlation analysis adjusted for age showed a significant correlation between PWV and DLCO, the extent of lung fibrosis (LF) on HRCT (p Conclusions: The increase of arterial stiffness is associated with the extent of lung fibrosis on HRCT, diffusion disturbance, and frequency of exacerbations among patients with chronic hypersensitivity pneumonitis.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124871042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Predictors of pulmonary-functional decline in systemic sclerosis: A university hospital experience 系统性硬化症肺功能下降的预测因素:一所大学医院的经验

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa4730

E. A. Vallejos, F. Felder, S. Leiva, J. Enghelmayer, R. Gomez, P. Rossi, Federico Zenón, G. Legarreta, S. Acuña, Mariano M Volpacchio

引用次数: 1

Clinical characteristics of anti-Jo-1-positive interstitial lung disease 抗jo -1阳性间质性肺疾病的临床特点

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa5183

Shihwan Chang, M. H. Shin, J. Shin, M. Park

引用次数: 0

Micro Array screening of microRNA markers of interstitial lung diseases for differential diagnostics 微阵列筛选间质性肺疾病的microRNA标志物用于鉴别诊断

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1358

G. Shepelkova, A. Zaytseva, V. Evstifeev, I. Stepanyan, E. Shmelev, V. Yeremeev

引用次数: 0

Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) tocilizumab (TCZ)治疗系统性硬化症(SSc)的3期临床试验中的肺功能保护

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.rct1883

C. Denton, Celia J. F. Lin, J. Goldin, G. Kim, M. Kuwana, Y. Allanore, A. Batalov, I. Butrimienė, P. Carreira, M. Matucci-Cerinic, O. Distler, D. Kaliterna, C. Mihai, M. Mogensen, M. Olesińska, J. Pope, G. Riemekasten, T. S. Rodriguez-Reyne, M. Santos, J. Laar, H. Spotswood, J. Siegel, A. Jahreis, D. Furst, D. Khanna

{"title":"Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)","authors":"C. Denton, Celia J. F. Lin, J. Goldin, G. Kim, M. Kuwana, Y. Allanore, A. Batalov, I. Butrimienė, P. Carreira, M. Matucci-Cerinic, O. Distler, D. Kaliterna, C. Mihai, M. Mogensen, M. Olesińska, J. Pope, G. Riemekasten, T. S. Rodriguez-Reyne, M. Santos, J. Laar, H. Spotswood, J. Siegel, A. Jahreis, D. Furst, D. Khanna","doi":"10.1183/13993003.congress-2019.rct1883","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.rct1883","url":null,"abstract":"Background: Anti–interleukin-6 receptor antibody TCZ showed clinically relevant lung function preservation (forced vital capacity [FVC]) in SSc patients (pts) in a phase 2 trial. Objective: Investigate TCZ vs placebo (PBO) in SSc in a phase 3 trial. Methods: Pts were randomized 1:1 to double-blind subcutaneous TCZ 162 mg or PBO per week (wk) for 48 wks. Primary endpoint: difference (TCZ vs PBO) in modified Rodnan skin score (mRSS) change from baseline (∆BL). Secondary endpoints: percent-predicted (pp)FVC; time to treatment failure (TTF; time from first study treatment to first occurrence of death, FVC decline >10%, mRSS increase ≥20% and mRSS ≥5, or occurrence of SSc complications); Health Assessment Questionnaire–Disability Index (HAQ-DI); pt/physician global assessment (Pt/PhGA) visual analog scale. Results: Of 106 PBO and 104 TCZ pts, 31% had previous/current interstitial lung disease based on their history. At wk 48, adjusted least-squares mean difference ∆BL mRSS PBO vs TCZ was –1.7 [95% CI: –3.8, 0.3], p=0.098). Cumulative distribution of ∆BL ppFVC (median [IQR] PBO –3.9 [–7.2, 0.6]; TCZ –0.6 [–5.3, 3.9] van Elteren nominal p=0.0015) and difference in mean ∆BL FVC at wk 48 (167 mL [95% CI: 83, 250]) favored TCZ. TTF hazard ratio (95% CI) was 0.6 (0.4, 1.1) numerically favoring TCZ (Cox proportional hazards p=0.082). No clinically meaningful difference was seen in mean (95% CI) difference ∆BL HAQ-DI –0.1 (–0.2, 0.1), PtGA –2.4 (–8.6, 3.7), PhGA –2.5 (–8.7, 3.8). Safety profile was consistent with SSc complications and TCZ treatment. Conclusion: The primary mRSS endpoint was not met. A clinically relevant difference in FVC was seen for TCZ vs PBO, with preservation of lung function.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"22 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132576001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Evaluation of drug-induced lung injury by ALK inhibitor: a single center retrospective analysis ALK抑制剂对药物性肺损伤的评价:单中心回顾性分析

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa4734

K. Koshikawa, J. Terada, M. Abe, S. Iwasawa, M. Sakayori, K. Tsushima, K. Tatsumi

引用次数: 0

Occupational dust exposure as a risk factor for MPO-ANCA-positive interstitial pneumonia 职业性粉尘暴露是mpo - anca阳性间质性肺炎的危险因素

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1361

N. Sakuma, H. Tojima, T. Hiroishi, Takuma Matsumura, Chie Koumura, Masakazu Kouno

{"title":"Occupational dust exposure as a risk factor for MPO-ANCA-positive interstitial pneumonia","authors":"N. Sakuma, H. Tojima, T. Hiroishi, Takuma Matsumura, Chie Koumura, Masakazu Kouno","doi":"10.1183/13993003.congress-2019.pa1361","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1361","url":null,"abstract":"Background: There are recent reports that silica exposure is linked with the production of myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA). Purpose: To investigate the involvement and effects of dust exposure on patients with MPO-ANCA-positive interstitial pneumonia, and to elucidate the clinical differences between exposed and non-exposed groups. Subjects and Methods: The sex, age at the time of the initial diagnosis, occupational history, smoking history, initial symptoms, imaging findings, diagnosis of microscopic polyangiitis, clinical course, and cause of death were investigated in 28 patients with MPO-ANCA-positive interstitial pneumonia that presented at our hospital between 1994 and 2018. Results: Fifteen of 28 patients (54%) had a history of occupational dust exposure. The dust-exposed group (68.3 ± 8.6 years) consists of all men with a history of smoking, the majority of whom initially presented with respiratory symptoms, with 8 patients diagnosed with MPA. Thirteen patients in the non-exposed group (72.7 ±5.7 years) included five men and eight women, seven of whom were smokers. The number of patients complicated with fever and renal dysfunction in terms of initial symptoms were higher in the non-exposed group than that in the exposed group, and nine were diagnosed with MPA. The five-year survival rate was approximately 35% for both groups, and there were no significant differences. Conclusion: Approximately half of the patients with MPO-ANCA-positive interstitial pneumonia at our hospital had a history of occupational dust exposure. Patients in the exposed and non-exposed groups were characterized by different backgrounds and clinical courses.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127784003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis CCL15作为超敏性肺炎预后生物标志物的临床应用

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa3600

Masako Watanabe, Y. Horimasu, H. Iwamoto, K. Yamaguchi, S. Sakamoto, T. Masuda, Taku Nakashima, S. Miyamoto, S. Ohshimo, K. Fujitaka, H. Hamada, N. Kohno, N. Hattori

{"title":"Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis","authors":"Masako Watanabe, Y. Horimasu, H. Iwamoto, K. Yamaguchi, S. Sakamoto, T. Masuda, Taku Nakashima, S. Miyamoto, S. Ohshimo, K. Fujitaka, H. Hamada, N. Kohno, N. Hattori","doi":"10.1183/13993003.congress-2019.oa3600","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.oa3600","url":null,"abstract":"Background: Chronic hypersensitivity pneumonitis (CHP) is characterized by lymphocytic inflammation and progressive fibrosis of the lung caused by a variety of inhaled antigens, and the prognosis of CHP patients is poor with the absence of established diagnosing criteria and effective therapeutic agent. Recently, we have founded that C-C motif chemokine ligand 15 (CCL15) mRNA highly expressed in CHP lung. Method: To investigate the usefulness of CCL15 as a clinical biomarker for CHP, CCL15 protein expression was investigated in lung tissue, serum and bronchoalveolar lavage fluid (BALF). Results: Immunohistochemistry investigations revealed high CCL15 expression in the lungs of CHP patients. Serum CCL15 levels in CHP patients (29.1 ± 2.1 μg/ml) were significantly higher than those in idiopathic pulmonary fibrosis patients (19.7 ± 1.3 μg/ml, p = 0.01) and in healthy subjects (19.5 ± 1.7 μg/ml, p = 0.003). When BALF CCL15 level was divided by BALF albumin level (BALF CCL15/Alb), it was significantly inversely correlated with forced vital capacity (β = -0.47, p = 0.0006), percentage of predicted carbon monoxide diffusion capacity of the lung (β = -0.41, p = 0.0048), and BALF lymphocyte count (β = -0.34, p = 0.01) in CHP patients. Multivariate Cox proportional hazards analysis revealed that high BALF CCL15/Alb and poor prognosis were statistically significantly independently correlated in CHP patients (HR = 1.1, 95% C.I. 1.03–1.18, p = 0.004). Conclusion: The results of the current study suggest that CCL15 may be a useful prognostic biomarker for CHP.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133005509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Childhood Interstitial Lung disease: A Tertiary Single Center Experience 儿童间质性肺病:三级单中心经验

ILD/DPLD of known origin Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa5188

T. Gursoy, A. Aslan, Z. Onay, T. S. Eyuboglu

引用次数: 0